Current Challenges in Personalized Cancer Medicine

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.

1. Vertical pathway targeting in cancer therapy
2. Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors
3. Targeting the tumor stroma as a novel treatment strategy for breast cancer – shifting from the neoplastic cell-centric to a stroma-centric paradigm
4. Targeting the Metabolic Microenvironment of Tumors
5. Targeted Therapy for Matastasis
6. Emerging Strategies for Targeting Cell Adhesion in Multiple Myelom
7. Targeting Notch Signaling for Cancer Therapeutic Intervention
8. Stem-like cells and therapy resistance in squamous cell carcinomas
9. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer
10. Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations
11. Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations
12. Chemoprevention of Melanoma
13. Whole genome and exome sequencing of melanoma: a step toward personalised targeted therapy
14. Targeted Therapy for Gastric Adenocarcinoma
15. HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
16. Apoptosis in Targeted Therapy Responses: The Role of BIM